1.	Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway Phase: Phase II, Phase I Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: MEVITEM, 2011-003372-37, NCT01601184
2.	GDC-0449 in Treating Adult Patients With Recurrent or Refractory Medulloblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 22 and over Sponsor: NCI, Other Protocol IDs: CDR0000648049, U01CA081457, PBTC-025B, NCT00939484
3.	Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: J1013, NA_00036883, NCT01088815
4.	Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS) Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: OCRD 201014, NCT01096732
5.	A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma (BCC) Phase: Phase II Type: Treatment Status: Active Age: 21 and over Sponsor: Pharmaceutical / Industry Protocol IDs: SHH4812g, GS01354, NCT01201915
6.	Phase II Study of Hedgehog Antagonist GDC-0449 in Pediatric Patients With Recurrent or Refractory Medulloblastoma Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 3 to 21 Sponsor: NCI Protocol IDs: PBTC-032, PBTC-032, NCT01239316
7.	A Study of Vismodegib in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MO25616, 2011-000195-34, NCT01367665
8.	Vismodegib for Treatment of Basal Cell Carcinoma Phase: Phase II Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 5110325, NCT01543581
9.	Trial Comparing the Effects of Intermittent Vismodegib Versus Photodynamic Therapy in Patients With Multiple Basal Cell Carcinomas Phase: Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 2011-077, ML28244, NCT01556009
10.	GDC-0449 and RO4929097 in Treating Women With Advanced Breast Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000662081, U01CA062487, WSU-2009-099, 8420, NCT01071564
11.	Phase I Study of Hedgehog Antagonist GDC-0449 Following Autologous Stem Cell Transplantation in Patients With High-Risk First Remission or Relapsed Multiple Myeloma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: JHOC-J1067, J1067, 8414, NCT01330173
12.	Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Phase: Phase I Type: Biomarker/Laboratory analysis, Diagnostic, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: MC1111, NCI-2011-03809, NCT01537107
13.	A Study of the Hedgehog Pathway Inhibitor Vismodegib in Patients With Advanced Solid Malignancies Including Hepatocellular Carcinoma With Varying Degrees of Renal or Hepatic Function Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GP27839, NCT01546519
14.	Cancer Stem Cells and Inhibition of Hedgehog Pathway Signaling in Advanced Pancreas Cancer: A Pilot Study of GDC-0449 in Combination With Gemcitabine Phase: No phase specified Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: UMCC 2010.003, HUM0036594, 2010-003, 8417, NCT01143415, NCT01195415
15.	An Observational Study of Treatment Patterns and Effectiveness and Safety Outcomes in Advanced Basal Cell Carcinoma and Basal Cell Carcinoma Nevus Syndrome Patients(RegiSONIC) Phase: No phase specified Type: Natural history/Epidemiology Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ML28296, NCT01604252
16.	Vismodegib in Treating Patients With Basal Cell Carcinoma Phase: No phase specified Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: SKIN0012, NCI-2012-01055, NCT01631331